Literature DB >> 10228070

Candida albicans mannan extract-protein conjugates induce a protective immune response against experimental candidiasis.

Y Han1, M A Ulrich, J E Cutler.   

Abstract

Candida albicans mannan extracts encapsulated in liposomes were previously used to stimulate mice to produce antibodies protective against candidiasis. In the present study, mannan-protein conjugates without liposomes were tested as vaccine candidates. Mannan extracts were coupled to bovine serum albumin, and isolated conjugates consisted of carbohydrate and protein at a ratio of 0.7-1.0. Vaccination of mice with the conjugate and an adjuvant yielded antiserum that contained Candida agglutinins. Vaccinated mice challenged with yeast cells had a mean survival time of 56 days, compared with <13 days for control groups. The antiserum protected naive animals against disseminated disease. Naive mice given the antiserum intravaginally developed 79% fewer fungal colony-forming units, compared with control groups. The serum-protective factor was stable at 56 degrees C and was removed by adsorption with yeast cells. It is concluded that the conjugate vaccine can induce protective antibody responses against experimental disseminated candidiasis and Candida vaginal infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10228070     DOI: 10.1086/314779

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  32 in total

1.  Vaccine and monoclonal antibody that enhance mouse resistance to candidiasis.

Authors:  Hong Xin; Jim E Cutler
Journal:  Clin Vaccine Immunol       Date:  2011-08-10

Review 2.  New concepts in antibody-mediated immunity.

Authors:  Arturo Casadevall; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

3.  Hybridoma passage in vitro may result in reduced ability of antimannan antibody to protect against disseminated candidiasis.

Authors:  Hong Xin; Jim E Cutler
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

4.  Design of a mimotope-peptide based double epitope vaccine against disseminated candidiasis.

Authors:  Hong Xin; Pati Glee; Abby Adams; Farhan Mohiuddin; Karen Eberle
Journal:  Vaccine       Date:  2019-03-28       Impact factor: 3.641

5.  A fungicidal monoclonal antibody protects against murine invasive candidiasis.

Authors:  María J Sevilla; Beatriz Robledo; Aitor Rementeria; María D Moragues; José Pontón
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

6.  Biological activities of naturally occurring antibodies reactive with Candida albicans mannan.

Authors:  Thomas R Kozel; Randall S MacGill; Ann Percival; Qing Zhou
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

Review 7.  Surface glycans of Candida albicans and other pathogenic fungi: physiological roles, clinical uses, and experimental challenges.

Authors:  James Masuoka
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

8.  Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated Candidiasis in recipients of a Candida albicans vaccine.

Authors:  Carla Bromuro; Antonella Torosantucci; Paola Chiani; Stefania Conti; Luciano Polonelli; Antonio Cassone
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

9.  Serological profiling of a Candida albicans protein microarray reveals permanent host-pathogen interplay and stage-specific responses during candidemia.

Authors:  A Brian Mochon; Ye Jin; Jin Ye; Matthew A Kayala; John R Wingard; Cornelius J Clancy; M Hong Nguyen; Philip Felgner; Pierre Baldi; Haoping Liu
Journal:  PLoS Pathog       Date:  2010-03-26       Impact factor: 6.823

Review 10.  Monoclonal antibody-based therapies for microbial diseases.

Authors:  Carolyn Saylor; Ekaterina Dadachova; Arturo Casadevall
Journal:  Vaccine       Date:  2009-12-30       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.